Bedaquiline, marketed as Sirturo, is a medication used to treat tuberculosis (TB). It is a diarylquinoline antimycobacterial drug developed by Janssen Pharmaceutica. It is used in the treatment of multi-drug resistant TB (MDR-TB). Bedaquiline is the first new anti-TB drug to be approved by the FDA in over 40 years. It is thought to work by inhibiting the bacterial enzyme ATP synthase, which is essential for the bacteria to generate energy. It is taken by mouth as a tablet.
Bedaquiline, also known by the brand name Sirturo, is a medication used to treat a specific type of tuberculosis (TB) called multidrug-resistant tuberculosis (MDR-TB). Here's a detailed description of its key characteristics:
Purpose:
- Bedaquiline is specifically used for adults with pulmonary MDR-TB. This means it targets TB infections that affect the lungs and have become resistant to at least two of the most commonly used TB medications.
- It is always used in combination with other anti-TB medications, typically at least three other drugs, to form a combination therapy regimen.
Mechanism of Action:
- Bedaquiline belongs to a class of drugs called diarylquinolines. It works by inhibiting the ATP synthase enzyme in Mycobacterium tuberculosis, the bacteria that causes TB. This enzyme is essential for the bacteria's energy production, and by inhibiting it, bedaquiline starves the bacteria and prevents its growth.
Important Considerations:
- Bedaquiline is a powerful medication with potential side effects that require careful monitoring by a healthcare professional. These side effects can include:
- QT prolongation: This can affect the heart rhythm and increase the risk of irregular heartbeats.
- Nausea, vomiting, and abdominal pain.
- Headache and dizziness.
- Joint pain.
- Increased risk of death: Studies have shown an increased risk of death in some patients taking bedaquiline compared to those not taking it. However, it's important to note that this increased risk needs to be weighed against the potential benefits of the medication, especially in severe MDR-TB cases.
Due to these considerations, bedaquiline is only used under the following circumstances:
- When other treatment options are not available or have failed.
- When the benefits of using bedaquiline are considered to outweigh the risks.
- Under the close supervision of a healthcare professional experienced in managing MDR-TB.
Overall:
Bedaquiline is a valuable weapon in the fight against drug-resistant tuberculosis but should be used cautiously and with careful monitoring due to its potential side effects. It's crucial to consult with a healthcare professional to determine the appropriate treatment plan for individual cases of MDR-TB.